A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 [erlotinib] in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Erlotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Sep 2009 Status changed from active, no longer recruiting to completed.
- 17 Sep 2005 New trial record.